Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP26A1 | O43174 | 5/20 | 0.53 |
| ▸ | POLB | P06746 | 1/20 | 0.53 |
| ▸ | HMOX2 | P30519 | 1/20 | 0.52 |
| ▸ | CYP19A1 | P11511 | 2/20 | 0.51 |
| ▸ | AURKA | O14965 | 1/20 | 0.50 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.50 |
| ▸ | RPS6KB1 | P23443 | 1/20 | 0.50 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.48 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24240734 | 0.81 | CYP26A1 (0.72) | CYP26A1RPS6KB1MAPK1 | |
| SCHEMBL3101929 | 0.79 | ROCK1 (0.67) | CYP26A1RPS6KB1MAPK1 | |
| SCHEMBL24240727 | 0.78 | CYP26A1 (0.64) | CYP26A1RPS6KB1MAPK1 | |
| SCHEMBL28796560 | 0.77 | CYP26A1 (0.60) | CYP26A1POLBHMOX2CYP19A1 | |
| SCHEMBL25335798 | 0.76 | CYP19A1 (0.67) | CYP26A1POLBHMOX2CYP19A1PTGS2 | |
| SCHEMBL7082419 | 0.76 | TBXAS1 (0.67) | POLBHMOX2CYP19A1 | |
| SCHEMBL24240730 | 0.75 | CYP51A1 (0.70) | CYP26A1 | |
| SCHEMBL28557139 | 0.74 | UTS2R (0.46) | POLB | |
| SCHEMBL10652258 | 0.74 | CYP19A1 (0.69) | POLBHMOX2CYP19A1 | |
| SCHEMBL11731922 | 0.73 | HMOX2 (0.56) | POLBHMOX2CYP19A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11241417-B2 | Compositions and methods for the treatment and prevention of neurological disorders | YUMANITY THERAPEUTICS, INC. (US) | 2022-02-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11241417-B2 | Compositions and methods for the treatment and prevention of neurological disorders | TARDBP, CYP51A1, TDP1 | CYP26A1 58/4885POLB 469/4885HMOX2 1229/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.